Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 12/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106729 | 0.87 | TNF (0.41) | TNFKAT2BP2RX3GAAALDH1A1 | |
| SCHEMBL5236477 | 0.84 | TNF (0.40) | TNFKAT2BGAAALDH1A1POLB | |
| SCHEMBL6106779 | 0.83 | GABRA1 (0.31) | MKNK2GAAPOLBNPSR1 | |
| SCHEMBL5235234 | 0.81 | TNF (0.41) | TNFKAT2BP2RX3GAAALDH1A1 | |
| SCHEMBL5238678 | 0.81 | TNF (0.41) | TNFKAT2BP2RX3GAAALDH1A1 | |
| SCHEMBL5239284 | 0.80 | ESR1 (0.38) | MKNK2GAAALDH1A1POLBNPSR1 | |
| SCHEMBL5232581 | 0.80 | ALDH1A1 (0.43) | GAAALDH1A1 | |
| SCHEMBL5237705 | 0.79 | L3MBTL1 (0.37) | TNFGAAALDH1A1 | |
| SCHEMBL5234123 | 0.77 | ESR1 (0.38) | TNFMKNK2GAAALDH1A1POLB | |
| SCHEMBL5233960 | 0.75 | GAA (0.40) | TNFP2RX3GAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | TNF 4760/4885KAT2B 2602/4885P2RX3 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.